Ying Liu

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley advised Harbour BioMed (HBM Holdings, HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in oncology and immunology, on its share subscription agreement with AstraZeneca.

Cooley advised Akeso (Hong Kong Stock Exchange code: 9926.HK), a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing and commercializing innovative medicines that address global medical needs, on its HK$1.9 billion (approximately US$250 million) follow-on public offering.

Cooley advised YH Entertainment, an established artist management company in China, on its HK$490 million ($63 million) global offering.

Cooley advised TI Cloud on its $71.7 million initial public offering of 43,530,000 shares at a public offering price of HK$12.85 per share. TI Cloud offers a broad array of cloud-native customer contact solutions that enable enterprises to engage in multichannel customer interactions. Partners Michael Yu and Will Cai led the Cooley team.